1.	Phase III Randomized Study of Dexamethasone Versus Prednisolone During Induction Therapy and Prolonged Versus Conventional Duration Asparaginase During Consolidation and Late Intensification Therapy in Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma Phase: Phase III Type: Treatment Status: Active Age: Under 18 Sponsor: Other Protocol IDs: EORTC-58951, NCT00003728
2.	Phase III Randomized Study of Induction and Maintenance Chemotherapy Regimens With Different Doses and Schedules of Methotrexate From the Berlin-Frankfurt-Munster-K2 Protocol With or Without Vinblastine in Children With Anaplastic Large Cell Lymphoma Phase: Phase III Type: Treatment Status: Active Age: Under 22 Sponsor: Other Protocol IDs: FRE-IGR-ALCL99, EU-20031, NHL2000/06, NCT00006455
3.	Phase III Study of Induction and Maintenance Therapy Comprising Etoposide, Dexamethasone, and Cyclosporine Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Primary Inherited or Severe and Persistent Secondary Hemophagocytic Lymphohistiocytosis Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Under 18 Sponsor: Other Protocol IDs: CCLG-LCH-2006-02, EU-20619, UKCCSG-HLH-2004, EUDRACT-2005-002187-28, NCT00334672
4.	Phase III Randomized Study of Low-Dose Versus High-Dose Vincristine and Combination Chemotherapy in Pediatric Patients With Intermediate-Risk Relapsed B-Precursor Acute Lymphoblastic Leukemia Phase: Phase III Type: Treatment Status: Active Age: 1 to under 30 Sponsor: NCI Protocol IDs: COG-AALL0433, AALL0433, NCT00381680
5.	Phase III Randomized Study of Pegasparaginase Verus E. coli Asparaginase With Combination Chemotherapy in Children With Newly Diagnosed Acute Lymphoblastic Leukemia Phase: Phase III Type: Treatment Status: Active Age: 1 to 17 Sponsor: NCI Protocol IDs: DFCI-05001, NCT00400946
6.	Phase I/II Pilot Study of Ifosfamide, Carboplatin, Etoposide, and Monoclonal Antibody SGN-30 in Pediatric Patients With CD30-Positive Recurrent Anaplastic Large Cell Lymphoma Phase: Phase II, Phase I Type: Treatment Status: Active Age: 1 to 21 Sponsor: NCI Protocol IDs: COG-ANHL06P1, ANHL06P1, NCT00354107
7.	Phase II Pilot Study of Epratuzumab Alone and in Combination With Re-Induction Combination Chemotherapy in Pediatric Patients With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (Part A closed to accrual as of 10/30/06) Phase: Phase II Type: Treatment Status: Active Age: 2 to 31 Sponsor: NCI Protocol IDs: COG-ADVL04P2, ADVL04P2, NCT00098839
8.	Phase II Study of Dose-Intensified Induction Therapy Comprising Cyclophosphamide, Vincristine, Prednisone, and Rituximab Followed by Consolidation Therapy Comprising Rituximab and High-Dose Cyclophosphamide in Adult Patients With Newly Diagnosed Burkitt or Atypical Burkitt Lymphoma or Leukemia Phase: Phase II Type: Treatment Status: Active Age: 30 and over Sponsor: NCI Protocol IDs: JHOC-J0409, JHOC-04-05-13-01, NCT00133991
9.	Applying Pediatric Regimens to Younger Adult Patients With Acute Lymphoblastic Leukemia (ALL) Phase: Phase II Type: Treatment Status: Active Age: 15 to 24 Sponsor: Other Protocol IDs: JALSG ALL202-U, NCT00131053
10.	Phase II Study of Rituximab, Cyclophosphamide, Vincristine, Doxorubicin Hydrochloride, and High-Dose Methotrexate (R-CODOX-M) Alone or Alternating With Rituximab and Ifosfamide, Etoposide Phosphate, and High-Dose Cytarabine (IVAC) in Combination With Intrathecal CNS Prophylaxis in Patients With Newly Diagnosed, HIV-Associated Burkitt's or Atypical Burkitt's Lymphoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: AMC-048, AMC-048, NCT00392834
11.	Phase II Study of Dasatinib in Combination With Intensified Chemotherapy in Young Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Phase: Phase II Type: Treatment Status: Active Age: 1 to 30 Sponsor: NCI Protocol IDs: COG-AALL0622, AALL0622, NCT00720109
12.	Phase II Pilot Study of Bortezomib in Combination With Intensive Reinduction Chemotherapy in Young Patients With Relapsed Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma Phase: Phase II Type: Treatment Status: Active Age: 1 to 31 Sponsor: NCI Protocol IDs: COG-AALL07P1, AALL07P1, NCT00873093
13.	177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer Phase: Phase II Type: Treatment Status: Approved-not yet active Age: Over 18 Sponsor: Other Protocol IDs: 0810010067, J591+Ketoconazole, NCT00859781
14.	Pilot Study of Intensified Systemic Chemotherapy and Reduced-Dose Radiotherapy in Patients With Acute Lymphoblastic Leukemia and Late Isolated CNS or Testicular Relapse Phase: No phase specified Type: Treatment Status: Active Age: 18 months to 29 years at relapse Sponsor: NCI Protocol IDs: COG-AALL02P2, AALL02P2, NCT00096135
15.	Randomized Study of Risk-Adjusted Therapies in Infants With Newly Diagnosed Acute Lymphoblastic or Biphenotypic Leukemia Phase: No phase specified Type: Treatment Status: Active Age: 365 days and under Sponsor: Other Protocol IDs: DCOG-INTERFANT-06, DCOG-INTERFANT-06, EUDRACT-2005-004599-19, NCT00550992, CCLG-LK-2006-10